SCHEMBL21991752

SCHEMBL21991752

N#Cc1ccc(C(=O)Nc2ccc(F)c(Cl)c2)cc1SC1CC=C(O)CC1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 2/20 0.43
RAB9A P51151 2/20 0.43
KCNQ3 O43525 2/20 0.42
KCNQ2 O43526 2/20 0.42
KCNE1 P15382 2/20 0.42
KCNQ1 P51787 2/20 0.42
MAPT P10636 1/20 0.41
MAP3K8 P41279 1/20 0.41
MAOB P27338 3/20 0.39
NPSR1 Q6W5P4 1/20 0.39
MALT1 Q9UDY8 1/20 0.39
TDP1 Q9NUW8 1/20 0.39
TP53 P04637 1/20 0.39
POLB P06746 1/20 0.39
MEN1 O00255 1/20 0.39
ALDH1A1 P00352 1/20 0.39
KMT2A Q03164 1/20 0.39
MAOA P21397 2/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
HDAC8 Q9BY41 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17792185 0.84 NPC1 (0.47) NPC1RAB9AKCNQ3KCNQ2KCNE1
SCHEMBL19473192 0.84 NPC1 (0.46) NPC1RAB9AKCNQ3KCNQ2KCNE1
SCHEMBL17792183 0.76 KCNQ3 (0.45) NPC1RAB9AKCNQ3KCNQ2KCNE1
SCHEMBL19473196 0.75 KCNQ3 (0.44) NPC1RAB9AKCNQ3KCNQ2KCNE1
SCHEMBL19473180 0.75 NPC1 (0.55) NPC1RAB9AKCNQ3KCNQ2KCNE1
SCHEMBL17784065 0.75 NPC1 (0.50) NPC1RAB9AKCNQ3KCNQ2KCNE1
SCHEMBL17784155 0.74 NPC1 (0.56) NPC1RAB9AKCNQ3KCNQ2KCNE1
SCHEMBL24771149 0.74 GRM4 (0.46) NPC1RAB9AKCNQ3KCNQ2KCNE1
SCHEMBL17784095 0.74 NPC1 (0.57) NPC1RAB9AKCNQ3KCNQ2KCNE1
SCHEMBL17792086 0.74 NPC1 (0.54) NPC1RAB9AKCNQ3KCNQ2KCNE1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3227262-B1 SULFIDE ALKYL AND PYRIDYL REVERSE SULFONAMIDE COMPOUNDS FOR HBV TREATMENT NOVIRA THERAPEUTICS INC (US) 2020-05-13 EP disclosed